Search / 45 results found

from
to

FRIDAY, Jan. 21, 2022 (HealthDay News) -- Vaccine effectiveness against symptomatic COVID-19 decreases by 20 weeks after the second dose of BNT162b2 or CHAdOx1-S, but limited waning is seen against COVID-19-related hospitalization and death, according to a study published online Jan. 12 in the New England Journal of Medicine.

TUESDAY, Jan. 11, 2022 (HealthDay News) -- Receipt of two doses of the Pfizer-BioNTech vaccine is associated with a high level of protection against multisystem inflammatory syndrome in children (MIS-C) among children aged 12 to 18 years, according to research published in the Jan. 7 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Moderna says booster shot can combat infection with Omicron variant. As the variant surges worldwide, the company released data showing that i…

FRIDAY, Dec. 17, 2021 (HealthDay News) -- Two doses of a pediatric Pfizer-BioNTech COVID-19 vaccine failed to spur an adequate immune response in children aged 2 to 5, the companies announced Friday.